Moreover, our study could not identify any association between CD133 tumor immunoexpression and patients’ age or gender (p = 0.026 and p = 0.592, respectively), which is in line with similar reports regarding the lack of a significant correlation between CD133 expression and CRC patients’ age (p = 0.267), gender (p = 0.93) or tumor location (p = 0.182) [18,25]. The gene discussed is PROM1; the disease is neoplasm.